Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefarnate for Residual Hypertriglyceridemia in Statin-Treated CHD
NCT03610321Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefarnate in hypertriglyceridemia (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Change in serum triglyceride level from baseline at 1 month. Status: unknown.
02
Drugs
gefarnate
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03610321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610321.